Hutchison China MediTech (Chi-Med) will stop its Phase III trial of surufatinib early following positive interim data showing the candidate met its primary endpoint of progression-free survival. The China trial was testing surufatinib in patients with advanced non-pancreatic neuroendocrine tumors. With a dual anti-angiogenesis, anti-microphage mechanism, surufatinib is designed to promote the body’s natural immune response to cancer. It is expected to be used together with other immunotherapies.
Source: China Biotoday